Loading

Aluda Pharmaceuticals

May 06, 2024
Session
Company Description: Aluda was founded to reexamine how fundamental cell processes are altered by disease, combining rational drug design with holistic objectives to make wider impact. We discovered that Vimentin, a filament protein with well-validated roles in disease, is druggable, creating a new kind of disease-modifying action that blocks how many cell processes that are normally protective and regenerative shift to over-stimulated and maladapted in disease. Lead small molecule ALD-R491 is ready for Phase I. Expert KOL and regulatory guidance outlines a viable plan to NDA filing in 36 months in sepsis, followed by expansion in Severe Crohn's with fibrotic strictures.

Aluda Pharmaceuticals
View all SUS 2024

BIO DOUBLE HELIX SPONSOR

Our sponsors help support BIO's mission to support and advocate for the biotechnology industry.

Loading

BIO HELIX SPONSORS